EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management.
- Author:
Chi Young OK
1
;
Ling LI
;
Ken H YOUNG
Author Information
- Publication Type:Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
- MeSH: B-Lymphocytes/*pathology/*virology; Diagnosis, Differential; Disease Management; Epstein-Barr Virus Infections/*complications; Herpesvirus 4, Human/*physiology; Humans; Lymphoproliferative Disorders/*diagnosis/*etiology/therapy
- From:Experimental & Molecular Medicine 2015;47(1):e132-
- CountryRepublic of Korea
- Language:English
- Abstract: Epstein-Barr virus (EBV) is a ubiquitous herpesvirus, affecting >90% of the adult population. EBV targets B-lymphocytes and achieves latent infection in a circular episomal form. Different latency patterns are recognized based on latent gene expression pattern. Latent membrane protein-1 (LMP-1) mimics CD40 and, when self-aggregated, provides a proliferation signal via activating the nuclear factor-kappa B, Janus kinase/signal transducer and activator of transcription, phosphoinositide 3-kinase/Akt (PI3K/Akt) and mitogen-activated protein kinase pathways to promote cellular proliferation. LMP-1 also induces BCL-2 to escape from apoptosis and gives a signal for cell cycle progression by enhancing cyclin-dependent kinase 2 and phosphorylation of retinoblastoma (Rb) protein and by inhibiting p16 and p27. LMP-2A blocks the surface immunoglobulin-mediated lytic cycle reactivation. It also activates the Ras/PI3K/Akt pathway and induces Bcl-xL expression to promote B-cell survival. Recent studies have shown that ebv-microRNAs can provide extra signals for cellular proliferation, cell cycle progression and anti-apoptosis. EBV is well known for association with various types of B-lymphocyte, T-lymphocyte, epithelial cell and mesenchymal cell neoplasms. B-cell lymphoproliferative disorders encompass a broad spectrum of diseases, from benign to malignant. Here we review our current understanding of EBV-induced lymphomagenesis and focus on biology, diagnosis and management of EBV-associated B-cell lymphoproliferative disorders.
